Anti-Hu CD3 Purified Low Endotoxin

*Gordon PR, Leimig T, Mueller I, Babarin-Dorner A, Holladay MA, Houston J, Kerst G, Geiger T, Handgretinger R: A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant. 2002 Jul;30 (2) :69-74., URL: https://www.ncbi.nlm.nih.gov/pubmed/12132044, *Li T, Wong VK, Yi XQ, Wong YF, Zhou H, Liu L: Matrine induces cell anergy in human Jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated T-cells signaling with concomitant up-regulation of anergy-associated genes expression. Biol Pharm Bull. 2010 Jan;33 (1) :40-6., URL: https://www.ncbi.nlm.nih.gov/pubmed/20045933, *Undale AH, van den Elsen PJ, Celis E: Antigen-independent acquisition of MHC class II molecules by human T lymphocytes. Int Immunol. 2004 Oct;16 (10) :1523-33., URL: https://www.ncbi.nlm.nih.gov/pubmed/15351785, *Quintana A, Schwindling C, Wenning AS, Becherer U, Rettig J, Schwarz EC, Hoth M: T cell activation requires mitochondrial translocation to the immunological synapse. Proc Natl Acad Sci U S A. 2007 Sep 4;104 (36) :14418-23., URL: https://www.ncbi.nlm.nih.gov/pubmed/17726106, *Trushin SA, Bren GD, Asin S, Pennington KN, Paya CV, Badley AD. Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol. 2005 Aug;79 (15) :9821-30., URL: https://www.ncbi.nlm.nih.gov/pubmed/16014943, *Lang P, Handgretinger R, Niethammer D, Schlegel PG, Schumm M, Greil J, Bader P, Engel C, Scheel-Walter H, Eyrich M, Klingebiel T: Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood. 2003 Feb 15;101 (4) :1630-6., URL: https://www.ncbi.nlm.nih.gov/pubmed/12393439, *Schlegel PG, Eyrich M, Bader P, Handgretinger R, Lang P, Niethammer D, Klingebiel T: OKT-3-based reconditioning regimen for early graft failure in HLA-non-identical stem cell transplants. Br J Haematol. 2000 Nov;111 (2) :668-73., URL: https://www.ncbi.nlm.nih.gov/pubmed/11122120, *Smith SL: Ten years of Orthoclone OKT3 (muromonab-CD3) : a review. J Transpl Coord. 1996 Sep;6 (3) :109-19; quiz 120-1., URL: https://www.ncbi.nlm.nih.gov/pubmed/9188368, *Katayose Y, Kudo T, Suzuki M, Shinoda M, Saijyo S, Sakurai N, Saeki H, Fukuhara K, Imai K, Matsuno S: MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res. 1996 Sep 15;56 (18) :4205-12., URL: https://www.ncbi.nlm.nih.gov/pubmed/8797593, *Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E, Dilber MS: Expansion of natural killer (NK) and natural killer-like T (NKT) -cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL) : a potential source for cellular immunotherapy. Leukemia. 2003 Oct;17 (10) :1973-80., URL: https://www.ncbi.nlm.nih.gov/pubmed/14513047

*Huang Y, Wange RL: T cell receptor signaling: beyond complex complexes. J Biol Chem. 2004 Jul 9;279 (28) :28827-30., URL: https://pubmed.ncbi.nlm.nih.gov/15084594/, *Alarcón B, Swamy M, van Santen HM, Schamel WW: T-cell antigen-receptor stoichiometry: pre-clustering for sensitivity. EMBO Rep. 2006 May;7 (5) :490-5., URL: https://pubmed.ncbi.nlm.nih.gov/16670682/, *Kuhns MS, Davis MM, Garcia KC: Deconstructing the form and function of the TCR/CD3 complex. Immunity. 2006 Feb;24 (2) :133-9., URL: https://pubmed.ncbi.nlm.nih.gov/16473826/